## Qin Li

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3578543/publications.pdf

Version: 2024-02-01

567144 395590 1,309 46 15 33 citations h-index g-index papers 50 50 50 1924 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study. Cancer Immunology, Immunotherapy, 2022, 71, 1443-1451.	2.0	13
2	NIK-SIX1 signalling axis regulates high glucose-induced endothelial cell dysfunction and inflammation. Autoimmunity, 2022, 55, 86-94.	1.2	3
3	Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. Journal of Hematology and Oncology, 2022, 15, 47.	6.9	121
4	Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19. MBio, 2022, 13, e0018122.	1.8	20
5	Targeting breast cancer with a combination of DNT and LAG3 checkpoint blockage and its mechanism. Immunity, Inflammation and Disease, 2022, 10, .	1.3	O
6	The Effect of Omega-3 Polyunsaturated Fatty Acid Supplementations on anti-Tumor Drugs in Triple Negative Breast Cancer. Nutrition and Cancer, 2021, 73, 196-205.	0.9	9
7	The main trunk of RCA may be the best choice of sequential vein graft distal end-to-side anastomosis. Perfusion (United Kingdom), 2021, , 026765912199057.	0.5	O
8	LAG3 and its emerging role in cancer immunotherapy. Clinical and Translational Medicine, 2021, 11, e365.	1.7	39
9	Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER-2â <sup>-</sup> ABC Patients: A Systematic Review and Meta-Analysis. Cancer Investigation, 2021, 39, 369-378.	0.6	7
10	The regulation of immune checkpoints by the hypoxic tumor microenvironment. PeerJ, 2021, 9, e11306.	0.9	22
11	Regorafenib plus PD-1 inhibitors in Chinese patients with microsatellite stable/mismatch repair proficient metastatic colorectal cancer: A real-world study Journal of Clinical Oncology, 2021, 39, e15585-e15585.	0.8	1
12	Immunogenicity and safety of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 2–5Âyears in China. Vaccine, 2021, 39, 3428-3434.	1.7	4
13	Clinical observation of the efficacy of PDâ€1/PDâ€11 inhibitors in the treatment of patients with advanced solid tumors. Immunity, Inflammation and Disease, 2021, 9, 1584-1595.	1.3	4
14	Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib. Frontiers in Cell and Developmental Biology, 2021, 9, 730240.	1.8	7
15	PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Clinical Breast Cancer, 2020, 20, e99-e111.	1.1	10
16	Combined blockade of ILâ€25, ILâ€33 and TSLP mediates amplified inhibition of airway inflammation and remodelling in a murine model of asthma. Respirology, 2020, 25, 603-612.	1.3	25
17	Addition of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer therapy. Bioscience, Biotechnology and Biochemistry, 2020, 84, 743-756.	0.6	10
18	The impaired anti-tumoral effect of immune surveillance cells in the immune microenvironment of gastric cancer. Clinical Immunology, 2020, 219, 108551.	1.4	12

#	Article	IF	CITATIONS
19	The application and prospect of CDK4/6 inhibitors in malignant solid tumors. Journal of Hematology and Oncology, 2020, 13, 41.	6.9	91
20	DNT Cell-based Immunotherapy: Progress and Applications. Journal of Cancer, 2020, 11, 3717-3724.	1.2	23
21	Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. Journal of Immunology Research, 2020, 2020, 1-11.	0.9	8
22	Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. Journal of Cancer, 2019, 10, 1764-1771.	1.2	11
23	Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. Journal of Hematology and Oncology, 2019, 12, 54.	6.9	416
24	Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2019, 138, 178-189.	2.0	31
25	<scp>IL</scp> â€33 induces production of autoantibody against autologous respiratory epithelial cells: a potential mechanism for the pathogenesis of <scp>COPD</scp> . Immunology, 2019, 157, 137-150.	2.0	14
26	Association between the degree of fibrosis in fibrotic focus and the unfavorable clinicopathological prognostic features of breast cancer. Peerl, 2019, 7, e8067.	0.9	14
27	Characteristics and prognostic values of traditional pathological parameters and advanced molecular subtypes in women in Beijing with operable breast cancer: a retrospective analysis. BMJ Open, 2018, 8, e021819.	0.8	0
28	Clinical outcomes comparison of 10Âyears versus 5Âyears of adjuvant endocrine therapy in patients with early breast cancer. BMC Cancer, 2018, 18, 977.	1.1	19
29	KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1. Biomedicine and Pharmacotherapy, 2018, 107, 1205-1209.	2.5	26
30	Protein arginine methyltransferase 8 gene enhances the colon cancer stem cell (CSC) function by upregulating the pluripotency transcription factor. Journal of Cancer, 2018, 9, 1394-1402.	1.2	20
31	Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer. BMC Gastroenterology, 2018, 18, 43.	0.8	4
32	Quantitative analysis of necrostatin-1, a necroptosis inhibitor by LC–MS/MS and the study of its pharmacokinetics and bioavailability. Biomedicine and Pharmacotherapy, 2017, 95, 1479-1485.	2.5	9
33	Aesthetic principles access thyroidectomy produces the best cosmetic outcomes as assessed using the patient and observer scar assessment scale. BMC Cancer, 2017, 17, 654.	1.1	10
34	NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells. International Journal of Oncology, 2017, 51, 1553-1562.	1.4	48
35	Comparison of Composition and Diversity of Bacterial Microbiome in Human Upper and Lower Respiratory Tract. Chinese Medical Journal, 2017, 130, 1122-1124.	0.9	14
36	Prognostic significance of HER3 in patients with malignant solid tumors. Oncotarget, 2017, 8, 67140-67151.	0.8	29

#	Article	IF	Citations
37	Correlation analysis between molecular subtypes and Nottingham Prognostic Index in breast cancer. Oncotarget, 2017, 8, 74096-74105.	0.8	9
38	Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?. Molecules, 2016, 21, 1331.	1.7	64
39	The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer. BMC Cancer, 2016, 16, 910.	1.1	13
40	Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients. Scientific Reports, 2015, 5, 15355.	1.6	5
41	Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Scientific Reports, 2015, 5, 15746.	1.6	30
42	The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis. PLoS ONE, 2015, 10, e0135829.	1.1	15
43	Continuous positive airway pressure treatment reduces cardiovascular death and non-fatal cardiovascular events in patients with obstructive sleep apnea: A meta-analysis of 11 studies. International Journal of Cardiology, 2015, 191, 128-131.	0.8	15
44	Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2014, 9, e104346.	1.1	39
45	Comparison of Gemcitabine Combined With Targeted Agent Therapy Versus Gemcitabine Monotherapy in the Management of Advanced Pancreatic Cancer. Clinical Therapeutics, 2014, 36, 1054-1063.	1.1	10
46	The function of human epidermal growth factor receptor-3 and its role in tumors (Review). Oncology Reports, 2013, 30, 2563-2570.	1.2	14